A cluster of specified microRNAs in peripheral blood as biomarkers for metastatic non-small-cell lung cancer by stem-loop RT-PCR

Li, Qingfeng; Mao, Weidong; Shu, Yongqian; Lin, Feng; Liu, Shaoping; Shen, Hua; Gao, Wen; Li, Suqing; Shen, Dong

doi:10.1007/s00432-011-1068-z

Cited by 71 publications

(48 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, miR-183 is highly represented in serum relative to urine. Serum levels of miR-183 have been described in case/control studies where significantly lower levels of miR-183 are observed in stage IV non-small-cell lung carcinoma versus controls-making it a potential biomarker target for lung cancer [20]. In addition, a clinically aggressive medulloblastoma has been linked to the pleiotropic effects of the miR-183 cluster [21].…”

Section: Results and Discussion (A) Exosome Isolation And Rna Recoverymentioning

confidence: 99%

Analysis of the RNA content of the exosomes derived from blood serum and urine and its potential as biomarkers

Zeringer

Barta

et al. 2014

Phil. Trans. R. Soc. B

321

247

View full text Add to dashboard Cite

Exosomes are tiny vesicles (30–150 nm) constantly secreted by all healthy and abnormal cells, and found in abundance in all body fluids. These vesicles, loaded with unique RNA and protein cargo, have a wide range of biological functions, including cell-to-cell communication and signalling. As such, exosomes hold tremendous potential as biomarkers and could lead to the development of minimally invasive diagnostics and next generation therapies within the next few years. Here, we describe the strategies for isolation of exosomes from human blood serum and urine, characterization of their RNA cargo by sequencing, and present the initial data on exosome labelling and uptake tracing in a cell culture model. The value of exosomes for clinical applications is discussed with an emphasis on their potential for diagnosing and treating neurodegenerative diseases and brain cancer.

show abstract

Section: Results and Discussion (A) Exosome Isolation And Rna Recoverymentioning

confidence: 99%

Analysis of the RNA content of the exosomes derived from blood serum and urine and its potential as biomarkers

Zeringer

Barta

et al. 2014

Phil. Trans. R. Soc. B

321

247

View full text Add to dashboard Cite

show abstract

“…With regard to the discriminatory capacity of miR-30d-5p, the favorable distinguishing ability revealed by both the SROC curves for GEO meta-analysis and the integrated meta-analysis hinted at the potential use of miR-30d-5p for screening of NSCLC. Considering the non-invasive nature of the circulating miRNA-based test, circulating miRNAs might conceivably surpass tissue mRNAs as the most attractive screening tools for NSCLC [43,44]. Therefore, a SROC curve was specially created for plasma miR-30d-5p levels.…”

Section: Discussionmentioning

confidence: 99%

Expression Signature and Role of miR-30d-5p in Non-Small Cell Lung Cancer: a Comprehensive Study Based on in Silico Analysis of Public Databases and in Vitro Experiments

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: The purpose of this study was to probe the clinico-pathological significance and the underlying mechanism of miR-30d-5p expression in non-small cell lung cancer (NSCLC). Methods: We initially examined the level of miR-30d-5p expression in NSCLC and non-cancer tissues using RT-qPCR. Then, a series of validation analyses including a meta-analysis of data from microarray chips in Gene Expression Omnibus (GEO), data mining of the cancer genome atlas (TCGA) and an integrated meta-analysis incorporating GEO microarray chips, TCGA data, in-house RT-qPCR and literature studies were performed to examine the clinico-pathological value of miR-30d-5p expression in NSCLC. In vitro experiments were further conducted to investigate the impact of miR-30d-5p on NSCLC cell growth. The molecular mechanism by which miR-30d-5p regulates the pathogenesis of NSCLC was probed through a bioinformatics analysis of its target genes. Moreover, dual luciferase reporter assay was conducted to verify the targeting regulatory relationship between miR-30d-5p and CCNE2. Results: Based on results from RT-qPCR, GEO meta-analysis, TCGA data mining and the integrated meta-analysis incorporating GEO microarray chips, TCGA data, in-house RT-qPCR and literature studies, miR-30d-5p expression was decreased in NSCLC tissues, and patients with NSCLC who presented with lower miR-30d-5p expression tended to display an advanced clinical progression. Significant pathways including the Mucin type O-glycan biosynthesis pathway, cell cycle pathway and cysteine and methionine metabolism pathway (all P< 0.05) revealed potential roles of the target genes of miR-30d-5p in the oncogenesis of NSCLC. Results from in vitro experiments indicated that miR-30d-5p could attenuate proliferation and viability of NSCLC cells. Among the 12 identified hub genes, nine genes including E2F3, CCNE2, SKP2, CDK6, TFDP1, LDHA, GOT2, DNMT3B and ST6GALNAC1 were validated by Pearson’s correlation test and the human protein atlas (HPA) database as targets of miR-30d-5p with higher probability. Specifically, dual luciferase reporter assay confirmed that CCNE2 was directly targeted by miR-30d-5p. Conclusion: In summary, miR-30d-5p expression is decreased in NSCLC, and it might play the role as tumor suppressor in NSCLC by regulating target genes.

show abstract

“…Many recent reports demonstrated that circulating miRNAs levels were significantly increased in cancer plasma or serum samples compared to control groups (31)(32)(33)(34)(35), including NSCLC (36,37). But some miRNAs expressions are lower in cancer groups than in control groups.…”

Section: Discussionmentioning

confidence: 99%

MicroRNAs in Body Fluids as Biomarkers for Non-Small Cell Lung Cancer: A Systematic Review

Huang

Deng

et al. 2014

Technol Cancer Res Treat

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) is one of the most common life-threatening malignant tumors. A test for early diagnosis of NSCLC needs to be not too invasive and not too heavy a burden for weakened patients. A series of studies reported various microRNAs (miRNAs) could be novel serum biomarkers for NSCLC. However, the diagnostic ability of different miRNA biomarkers varies among the reports. The goal of this study was to perform a systematic review to examine the effect of miRNAs on NSCLC-related outcomes. We system- The range of diagnostic odds ratio (DOR) was 6.52983.38. The current evidence indicates that miRNAs in body fluids show high accuracy in identifying NSCLC, and could be a useful screening tool for diagnosing NSCLC patients.

show abstract

A cluster of specified microRNAs in peripheral blood as biomarkers for metastatic non-small-cell lung cancer by stem-loop RT-PCR

Cited by 71 publications

References 32 publications

Analysis of the RNA content of the exosomes derived from blood serum and urine and its potential as biomarkers

Analysis of the RNA content of the exosomes derived from blood serum and urine and its potential as biomarkers

Expression Signature and Role of miR-30d-5p in Non-Small Cell Lung Cancer: a Comprehensive Study Based on in Silico Analysis of Public Databases and in Vitro Experiments

MicroRNAs in Body Fluids as Biomarkers for Non-Small Cell Lung Cancer: A Systematic Review

Contact Info

Product

Resources

About